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Reference centresAbstract Purpose: The optimal management of rare tumours (i.e. from accurate diagnosis to
management in reference centres) is a public health challenge. In 2009, the French National
Cancer Institute (INCa) identified and financially supported the two expert networks for path-
ological and clinical diagnosis and management of soft tissue tumours.
Methods: The activities of both networks were prospectively collected using a nationwide
database (rreps.org). Data describing the diagnosis management of 863 successive cases of des-
moids tumours (DT) were prospectively collected from 2010 to 2013 and analysed.
Results: The number of confirmed DT constantly improved from January 2010 to December
2013 (from 173 to 273 cases per year); the expected incidence ranged from 132 to 330 cases/
year. The rate of cases diagnosed with core-needle biopsies and CTNNB1 mutational status
analysis increased from 30.6 to 40.7% and from 87.8 to 94.1%, respectively. The mean delay
for pathological diagnosis confirmation constantly decreased from 107 to 47 d. Among the
846 adult patients, 414 (48.9%) patients were treated by reference centres. The rate of patients
managed by reference centres constantly increased with time from 36.9 to 49.5% since 2010.
The median management time of the referral centres constantly decreased from 440 to 67 d.
Conclusion: The two expert networks worked synergistically and improved diagnosis modal-
ities of rare desmoid tumours at a national level. The impact of management by expert net-
works on the outcome will be prospectively analysed in the future.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A desmoid tumour (DT), also called aggressive fibro-
matosis, is a monoclonal fibroblastic proliferation that is
regarded as benign. DTs are very rare, with an estimated
incidence of two to five cases per million of inhabitants
in European countries. According to the literature, the
median age at diagnosis of DT is about 35 years, and the
majority of patients are women [1]. About 15% of DT
cases are related to familial adenomatous polyposis
(FAP) [2e3]. The pathological diagnosis of DT is diffi-
cult. The somatic mutation of CTNNB1 in cases unre-
lated to FAP appears as an important diagnostic marker
[4e6]. The clinical management of DT is very complex
and requires a multidisciplinary approach because of the
unpredictable disease course (i.e. from spontaneous
regression to life-threatening tumour progression), het-
erogeneous nature of the disease (i.e. mesenteric location
associated with FAP, abdominal wall DT associated
with pregnancy, limb locations, and neck, or shoulders
location), and functional consequences of disease [7].
Experts currently recommend a wait-and-see policy as
the first therapeutic approach rather than a uniform
front line en bloc surgery [8e9]. This wait-and-see
approach requires core-needle biopsy. The durationfrom the recognition of the first symptom and diagnosis
to adequate treatment is often long in patients with DT
because of the rarity of disease.
In 2009, the French National Cancer Institute (INCa)
organised and labelled two expert networks dedicated to
the management of adult sarcomas, gastro-intestinal
stromal tumours (GISTs) and DTs. The pathologist
network (RRePS; “Re´seau de Relecture en Pathologie
des Sarcomes”, https://rreps.sarcomabcb.org/home.htm)
is in charge of systematic reviewing diagnosed or sus-
pected cases regardless of where the diagnosis was per-
formed (i.e. general hospital and private clinic). This
network is also responsible for conducting molecular
diagnostic tests (e.g. exon 3 CTNNB1 mutation in DT
cases). The clinical network, NetSarc Network for clin-
ical management of Sarcoma”, is a network of referral
centres for the clinical management of adult sarcomas,
GISTs, and DTs. The RRePS and NetSarc networks
include 22 and 26 centres, respectively, covering the
French territory and share an online database. This
online database is prospectively annotated and enables
the description of diagnoses in real-time. In parallel, the
French patient advocacy group, SOS Desmoı¨de, has
supported the implementation of both networks, annual
meetings with patients and caregivers, and updating of
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both networks and provided the list of responsible and
dedicated multidisciplinary committees.
The objective of this report was to describe, for the
first time, the impact of the setup of these two-labelled
networks for the management of DT in France.
2. Patients and methods
2.1. Study design
The present study is a descriptive study of the both
labelled reference centre networks in France, on the first
4 years of network implementation. There was no
formal planned study design or statistical-based sample
size calculation. The present study is an exploratory
analysis of prospectively collected data at a national
level.
2.2. Role of expert pathologists networks (RRePs)
The RRePs network is led by Pr. JM Coindre, and is
responsible for the following: (1) second opinion for
every suspected or diagnosed case of sarcoma, GIST,
and DT, and (2) when necessary, molecular biology
confirmatory tests (e.g. analysis of exon 3 CTNNB1
mutations). Second opinion and molecular biology
confirmatory tests are not charged to the pathologist
outside the network. The RRePS networks account for
22 referral centres, covering the French territory, and
includes three coordinating centres (i.e. Institut Bergo-
nie´, Centre Le´on Be´rard, and Gustave Roussy). The
pathologists of the RRePS network systematically
reviewed complex cases during meetings held every 3
months, which was followed by undergoing training
courses for diagnosis of connective tissue tumours (full
list of contributors available on the Appendix).
2.3. Role of referral clinical centres
The NetSarc network is led by Pr. JY Blay, and is
responsible for the multidisciplinary management of
adult sarcoma, GISTs, and DTs. This network is also in
charge of clinical research development dedicated to
adult connective tissue tumours. Similar to RRePS, the
three coordinating centres (i.e. Institut Bergonie´, Centre
Le´on Be´rard, and Gustave Roussy) are responsible for
coordinating the entire network. Both networks
(i.e. RRePs and NetSarc) are in charge of translational
research development and epidemiological studies (full
list of contributors available on the Appendix).
2.4. Shared database
Both NetSarc and RRePs networks share an online
database (https://rreps.sarcomabcb.org/home.htm),
which provided some key indicators of activity Allpatients were anonymised. The main characteristics of
the tumours and patients, course of disease, and nature
of treatments were prospectively collected. The data
were collected by pathologists, physicians, and clinical
research assistants of the networks. Data quality was
ensured by training all members, pre-testing, and per-
forming consistency checks during data entry. Further-
more, the data were evaluated by the clinical research
assistants of the three major expert networks during
onsite audit and regular database queries.
2.5. Role of the French National Cancer Institute (INCa)
The INCa has funded the setup and the operation of the
networks for 4 years (2010, 2011, 2012 and 2013),
including the development of the online database, costs
related to second opinion and molecular biology
confirmatory tests, and costs related to the management
of the database. Nevertheless, this label provided by
INCa was not associated with financial or regulatory
constraints; therefore, physicians and pathologists
outside the networks were free to refer (or not) the cases
and patients to referral centres.
2.6. Role of the patient advocacy group SOS Desmoı¨de
The SOS Desmoı¨de supported the labelling of the
RRePS and NetSarc networks. This association has
written and distributed leaflets about the optimal man-
agement of DT, updated its website (http://www.sos-
desmoide.asso.fr/) to include the list of referral centres,
and organised annual meetings for the patients and
caregivers to promote the role of referral centres.
2.7. Ethical considerations
The data-collection and further analysis were approved
by the ethics committees as required by the applicable
national legislation (approval by the ‘Comite´ consultatif
sur le traitement de l’information en matie`re de recher-
che dans le domaine de la sante´’ on 16th September
2010, authorisation number 10.403 and approval by the
‘Comite´ National Informatique et Liberte´’ on the 15th
July 2013, authorisation number 910390). Signed
informed consents were obtained from all study partic-
ipants before registration.
2.8. Statistical analysis
The following different key indicators were analysed:
number of confirmed cases, method for initial diagnosis
(i.e. core-needle biopsy, open biopsy, or surgical spec-
imen), diagnosis performed within or outside the
network, analysis of CTNNB1 mutation, patient
managed at expert clinical centres, delay between bi-
opsy/surgery and confirmation of diagnosis, and delay
between biopsy/surgery and first consultation at clinical
Fig. 1. Patient disposition.
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numbers and percentages, median and extreme values,
or means and standard deviations, were obtained for the
key indicators. Comparisons of indicator distributions
per year were based on Chi-squared tests or Student t
tests. The identification of risk factors for management
in referral clinical centres was based on Chi-squared
tests. The analysis of the delay between initial biopsy/
surgery and diagnosis confirmation or first consultation
at expert centres was based on KaplaneMeier curves
and log-rank tests. The initial date was defined as the
date of initial biopsy of the initial surgical procedure.
Statistical analyses were conducted using STATA/SE
version 13.1 statistical software (StataCorp, LP, College
Station, Texas).
3. Results
3.1. Activity of the expert pathologists’ network
From 1st January 2010 to 31st December 2013, the
expert pathologists confirmed the diagnosis of DT in
861 cases. The median age at diagnosis was 44 years
(range, 6e90 years). The male/female sex ratio was 288/
573. This cohort included 15 paediatric cases (<15
years), which represented 1.7% of cases. The median
tumour size at diagnosis was 5.5 cm (range, 1e55 cm).Table 1
Evolution of key indicators during the 4 years following the labelling of re
Confirmed cases: n
Diagnosed within the network: n (%)
Diagnosed outside the network and then confirmed by expert pathologists
CTNNB1 mutation analysis: n (%)
Core-needle biopsy: n (%)
Managed by clinical reference centres: n (%)The five most common primary sites for the tumours
were abdominal wall (259/861, 30.1%), intra-abdominal
(188/861, 21.8%), chest wall (116/861, 13.4%), shoulder
(33/861, 3.8%), and breast (33/861, 3.8%). The number
of cases diagnosed within the referral centres was rela-
tively constant during the study (80, 65, 90, and 81 cases
in 2010, 2011, 2012, and 2013, respectively). In contrast,
the number of cases suspected outside the network and
then confirmed by expert pathologists had constantly
increased during the study (93, 109, 151, and 192 cases
in 2010, 2011, 2012, and 2013, respectively). During
these 4 years, the rate of cases diagnosed outside the
referral centres was 72.6% (625/861).
Five hundred and forty-five cases, initially diagnosed
outside the referral centres, were systematically reviewed
by expert pathologists (Fig. 1). Prior to the systematic
review, DT was diagnosed in 389/545 cases (71.3%), and
156/545 cases (28.7%) had another diagnosis. The most
common misdiagnoses were sarcoma in 35/156 cases
(22.4%), GIST in 26/156 cases (16.6%), nodular fasciitis
in 20/156 cases (12.8%), and leiomyoma in 6/156 cases
(3.8%).
During the study, the rate of cases with analysis of
CTNNB1 mutation was constant [87.8% in 2010 (152/
173), 97.1% in 2011 (169/174), 96.3% in 2012 (232/241),
and 94.1% in 2013 (257/273); Table 1]. During the 4
years of the study, the results of the CTNNB1 mutationference networks.
2010 2011 2012 2013 p
173 174 241 273 e
80 (46.2) 65 (33.8) 90 (34.8) 81 (29.7) 0.001
: n (%) 93 (53.8) 109 (66.2) 151 (65.2) 192 (70.3)
152 (87.8) 169 (97.1) 232 (96.3) 257 (94.1) 0.070
53 (30.6) 61 (35.0) 105 (43.5) 111 (40.7) 0.030
61 (36.9) 90 (51.7) 128 (53.1) 135 (49.5) 0.004
Table 3
Factors associated with management in reference clinical centres.
Not managed by
reference centres,
n (%) n Z 432
Managed by
reference centres,
n (%) n Z 414
p
Categorical parameters
2010 104 (63.1) 61 (36.9) 0.004
2011 91 (50.0) 91 (50.0)
2012 106 (44.9) 130 (55.1)
2013 131 (50.0) 132 (50.0)
Women 267 (50.0) 298 (50.0) 0.016
Men 165 (58.8) 116 (41.2)
Bone DT 2 (66.4) 1 (33.3) 0.02
Soft tissue DT 357 (49.2) 369 (50.8)
Visceral DT 73 (62.4) 44 (37.6)
Abdominal wall DT 128 (49.5) 131 (50.5) 0.82
Other primaries 286 (50.3) 283 (49.7)
Presence of CTNNB1
mutation
302 (70.0) 278 (67.2) 0.316
Absence of CTNNB1
mutation
84 (19.4) 73 (17.6)
Data unavailable 46 (10.6) 63 (15.2)
Open surgical biopsy 46 (56.1) 36 (43.9) 0.00001
Resection 279 (62.1) 170 (37.8)
Core-needle biopsy 107 (44.0) 208 (66.0)
Continuous parameters
Age (years) 48  4 44  4 0.005
DT size (mm) 94  7 70  7 0.79
DT, desmoid tumours.
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mutation in 580/846 cases (68.6%), absence of mutation
in 157/846 cases (18.5%), and not analysable in 109/846
cases (12.9%). According to collected data at the time of
DT diagnosis, only 25/846 adult patients (2.9%) were
known to be affected by Gardner syndrome.
The median time from initial biopsy/surgery to
diagnosis confirmation constantly decreased during the
study [107 d in 2010 (range, 0e605 d), 50 d in 2011
(range, 0e275 d), 49 d in 2012 (range, 0e75 d), and 47
d in 2013 (range, 0e92 d); p < 0.0001)].
3.2. Activity of clinical referral centres
During the 4 years of this study, 846 adults were
confirmed to have DT by expert pathologists. Among
these 846 patients, 414 patients were at least partly
managed by clinical reference centres (48.9%). The rea-
sons for management within clinical reference centres
were as follows: initial management (207/414, 50.0%),
second opinion (160/414, 38.6%), and relapse/progres-
sive disease (47/414, 11%). The method for diagnosing
DT was remarkably different between inside and outside
the reference network centres (Table 2). Core-needle
biopsy was the predominant method for diagnosis in-
side the referral network (195/316; 61.7%). Surgical
resection was the predominant method for diagnosis
outside the referral network (349/545; 64.0%; Table 2).
The rate of cases diagnosed with core-needle biopsies
was increased during the study [53/173 (30.6%) in 2010,
61/174 (35.0%) in 2011, 105/241 in 2012 (43.5%), and
111/273 in 2013 (40.7%)].
The rate of cases at least partly treated and/or
managed by reference centres was constantly increased
from 36.9% (61/173) in 2010 to 49.5% (135/273) in 2013
(Table 1). Being a woman, being young, and having a
soft tissue rather than visceral DT were factors associ-
ated with the management in reference centres (Table 3).
The median time from initial diagnostic procedure
(i.e. biopsy or surgery) to the first consultation within
reference centres was dramatically decreased during the
study [440 days in 2010 (range, 0e1203 d) to 62 d in
2013 (range, 0e345 d); p < 0.0001; Fig. 2].
4. Discussion
The key findings of this study could be summarised as
follows: (1) most of the DT cases were diagnosed outsideTable 2
Methods for diagnosing desmoid tumours.
Reference centres, n (%)
n Z 316
Outside the network
n (%) n Z 545
Core-needle biopsy 195 (61.7%) 120 (22.0%)
Open biopsy 22 (6.9%) 62 (11.3%)
Surgical specimen 83 (26.3%) 349 (64.0%)
Unknown 16 (5.0%) 14 (2.5%)the referral centres, and then confirmed by expert pa-
thologists within the expert network, (2) 1/3 of the DT
cases were misdiagnosed outside the network, and (3)
the implementation of the two networks resulted in a
significant increase in the total number of confirmed
cases matching the expected incidence in this country, a
decrease in the delay for obtaining diagnosis confirma-
tion and the time interval between initial diagnostic
procedure and first consultation at the referral centre,
and an increase in the percentage of cases at least partly
managed by reference clinical centres. The factors
independently associated with management within
referral centres were being a woman, being young, and
having a soft tissue DT.
The characteristics of our cohort were mainly in
accordance with literature data [4,6]. However, the rate
of men affected by DT and the median age were higher
than expected. According to the present study, only 3%
of patients were known to be affected by FAP at the
time of DT diagnosis. We systematically analysed the
somatic mutation of CTNNB1 in the incidence cases.
The CTNNB1 mutation was absent in about 20% of
cases, suggesting that about 20% of patients with DT
could be affected by FAP and require colonoscopy to
exclude underlying unknown FAP [2e3]. This needs to
Fig. 2. Median time between initial procedures to first consultation at reference centres.
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than expected.
To our knowledge, this was the first report in which
the setup of expert networks for diagnosis and man-
agement of rare cancers at a national level was shown to
significantly improve the adherence to optimal clinical
practice guidelines in a relatively short period. The
importance of centralising the management of cancer
patients has been previously reported in different set-
tings (i.e. primary locations and continents) [10e14],
and especially in cases of connective tissue tumours
[15e20].
In the present report, the centralisation of DT cases
for diagnosis and initial management was associated
with the predominant use of core-needle biopsy in
reference centres and likely to result in less invasive and
less expensive management procedures and the possi-
bility to discuss the best strategy, including non-surgical
approaches. In contrary, primary surgical resection
without biopsy (“whoops procedures”) remained the
predominant method used for diagnosing DT outside
the network, and most of these surgical procedures were
not conducted according to guidelines for oncologic
surgery. This front line surgery obviously prevented the
option of wait and see.
The present study has some limitations. This was not
a national registry and its completeness could be dis-
cussed. Firstly, we analysed some key indicators of ac-
tivity; however, the impact of the labelling of networks
on changes in decision-making, therapeutic options, and
patient outcomes was not evaluated. Given the benign
nature of DT and its unpredictable course, additional
years of follow-up are needed to assess this impact. At
the end of the study, about 50% of diagnosed DT cases
were at least partly managed by clinical reference cen-
tres, which was disappointing. However, the designationof the networks was not associated with financial and
regulatory constraints and physicians outside the
network were free to refer patients as required.
Furthermore, the observed improvement could not be
directly related to the sole setup of the labelling net-
works because there were some additional confounding
events (i.e. the role of the patient advocacy group that
largely distributed information to patients and care-
givers, and provision of second opinions and molecular
biology confirmatory tests free of charge for patholo-
gists outside the network). Further analyses might
include the assessment of clinical outcomes inside and
outside the clinical expert networks, impact of misdi-
agnosis correction, and amount of money saved by
avoiding inappropriate surgical procedures. Further-
more, we have launched three dedicated clinical trials to
assess the risk/benefit ratio of the wait-and-see
approach, activity of pazopanib compared to metho-
trexate/vinblastine in relapsing or progressive DT, and
the activity of cryotherapy in refractory DT.
The designation of expert networks for diagnosis and
management of connective tissue tumours was associ-
ated with significant improvements of key indicators
applied to the diagnosis and initial management of DT.
Author contributions
NP, JYB and JMC designed and supervised the study,
analysed the data and wrote the paper. All other authors
have supervised clinical patient management, reviewed
and approved the paper.
Conflict of interest statement
All authors declare that they have no conflict of
interest.
N. Penel et al. / European Journal of Cancer 58 (2016) 90e9696Role of the funding source
INCa (the French Cancer Agency) had funded this
study. INCa did not participate to study design discus-
sion, data-collection and data-analysis or interpretation
of the data. INCa did not interfere with the manuscript
writing or with the decision to submit the manuscript.
Acknowledgements
The authors thank the clinical research assistants for
coordinating data collection, the data-manager and the
informaticians for database development. The
authors thank the representatives of the reference cen-
tres and (see full list of contributors as appendix) the
French Patient Advocacy Group SOS Desmoı¨de for
their help and support.
Appendix. Supplementary data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.ejca.2016.02.008.
References
[1] van Broekhoven DL, Gru¨nhagen DJ, den Bakker MA, van
Dalen T, Verhoef C. Time trends in the incidence and treatment
of extra-abdominal and abdominal aggressive fibromatosis: a
population-based study. Ann Surg Oncol 2015;22:2817e23.
[2] Sinha A, Tekkis PP, Gibbons DC, Phillips RK, Clark SK. Risk
factors predicting desmoid occurrence in patients with familial
adenomatous polyposis: a meta-analysis. Colorectal Dis 2011;13:
1222e9.
[3] Schiessling S, Kihm M, Ganschow P, Kadmon G, Bu¨chler MW,
Kadmon M. Desmoid tumour biology in patients with familial
adenomatous polyposis coli. Br J Surg 2013;100:694e703.
[4] Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-
Vince D, et al. Prognostic factors influencing progression-free
survival determined from a series of sporadic desmoid tumors: a
wait-and-see policy according to tumor presentation. J Clin Oncol
2011;29:3553e8.
[5] Le Guellec S, Soubeyran I, Rochaix P, Filleron T, Neuville A,
Hosein I, et al. CTNNB1 mutation analysis is a useful tool for the
diagnosis of desmoid tumors: a study of 260 desmoid tumors and
191 potential morphologic mimics. Mod Pathol 2012;25:1551e8.
[6] Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le
Cesne A, et al. CTNNB1 45F mutation is a molecular prognos-
ticator of increased postoperative primary desmoid tumor recur-
rence: an independent, multicenter validation study. Cancer 2013;
119:3696e702.[7] Rigaux P, Lefebvre-Kuntz D, Penel N, “SOS Desmoı¨de”. Pain
burden in desmoid tumor patients: a survey of the French
Advocacy Group SOS Desmoid. Bull Cancer 2015;102:213e6.
[8] Colombo C, Miceli R, Le Pe´choux C, Palassini E, Honore´ C,
Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type
fibromatosis: surgical resection can be safely limited to a minor-
ity of patients. Eur J Cancer 2015;51:186e92.
[9] Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F,
Hohenberger P, et al. Management of sporadic desmoid-type
fibromatosis: a European consensus approach based on patients’
and professionals’ expertise e a sarcoma patients EuroNet and
European Organisation for Research and Treatment of Cancer/-
Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer
2015;51:127e36.
[10] Branagan G, Davies N. Early impact of centralization of oeso-
phageal cancer surgery services. Br J Surg 2004;91:1630e2.
[11] Hohenberger W, Merkel S, Hermanek P. Volume and outcome in
rectal cancer surgery: the importance of quality management. Int
J Colorectal Dis 2013;28:197e206.
[12] Gooiker GA, Lemmens VE, Besselink MG, Post PN, Van de
Velde CJ, Tollenaar RA, et al. Impact of centralization of
pancreatic cancer surgery on resection rates and survival. Br J
Surg 2014;101:1000e5.
[13] Suzumara S, Ioka A, Nakayama T, Tsukuma H, Oshima A,
Ishikawa O. Hospital procedure volume and prognosis with
respect to testicular cancer patients: a population-based study in
Osaka, Japan. Cancer Sci 2008;99:2260e3.
[14] Harding MJ, Paul J, Gillis CR, Kaye SB. Management of ma-
lignant teratoma: does referral to a specialist unit matter? Lancet
1993;341:999e1002.
[15] Clasby R, Tilling K, Smith MA, Fletcher CD. Variable man-
agement of soft tissue sarcoma: regional audit with implications
for specialist care. Br J Surg 1997;84:1692e6.
[16] Rossi CR, Vecchiato A, Mastrangelo G, Montesco MC,
Russano F, Mocellin S, et al. Adherence to treatment guidelines
for primary sarcomas affect patient survival: a side study of the
European CONnective TIssue CAncer NETwork (CON-
TICANET). Ann Oncol 2013;24:1685e91.
[17] Ligier K, Maynou C, Leroy X, Robin YM, Martin P, Clisant S,
et al. Improvement of the initial management of sarcomas after
dissemination of evidence-based guidelines depends on the pri-
mary sarcoma location: a population-based study. BMC Cancer
2015;15:218.
[18] Gustafson P, Dreinho¨fer KE, Rydholm A. Soft tissue sarcoma
should be treated at a tumor center. A comparison of quality of
surgery in 375 patients. Acta Orthop Scand 1994;65:47e50.
[19] Sampo MM, Ro¨nty M, Tarkkanen M, Tukiainen EJ,
Bo¨hling TO, Blomqvist CP. Soft tissue sarcoma e a population-
based, nationwide study with special emphasis on local control.
Acta Oncol 2012;51:706e12.
[20] Ray-Coquard I, Thiesse P, Ranche`re-Vince D, Chauvin F,
Bobin JY, Sunyach MP, et al. Conformity to clinical practice
guidelines, multidisciplinary management and outcome of treat-
ment for soft tissue sarcomas. Ann Oncol 2004;15:307e15.
